Prevention of gram-positive infections in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomized controlled trial of vancomycin.
Between January 1986 and June 1988, 155 patients (73 children and 82 adults), who were candidates for bone marrow transplantation, were included in a randomized controlled trial (75 patients in vancomycin group and 80 patients in the group without vancomycin) to evaluate the efficiency of a short course of vancomycin (10 mg/kg i.v. every 6 hours, day-5 to +1) in decreasing the incidence of Gram-positive infections during aplasia after high-dose chemotherapy and bone marrow transplantation. There was no statistical difference in the occurrence of documented septicemia, documented coccus Gram-positive infections, or fever of unknown origins during aplasia in the 2 groups. Thus, short prophylactic treatment with vancomycin proved inefficient in reducing morbidity due to infection after high-dose chemotherapy and bone marrow transplantation.
Teinturier
C
C
Department of Pediatric Oncology, Institut Gustave Roussy, Villejuif, France.
Hartmann
O
O
Lemerle
J
J
Benhamou
E
E
Maraninchi
D
D
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D016908:Gram-Positive Bacterial Infections / Q000517:prevention & control*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D014640:Vancomycin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014640:Vancomycin